NCT00077142View on ClinicalTrials.gov

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

July 31, 2005

Study Completion Date

August 31, 2005

Conditions
Liver Cancer
Interventions
DRUG

TAC-101

Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.

Trial Locations (1)

77030-4009

MD Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00077142 - TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | Biotech Hunter | Biotech Hunter